Donor, recipient, and transplant characteristics of 119 syngeneic HCTs
Factor . | No. (%) or mean (range) . |
|---|---|
| Age | 42 (17-68) |
| Sex | |
| Female | 49 (41) |
| Male | 70 (59) |
| Parity in female donors, N = 45 | |
| Nulliparous | 11 (22) |
| Parous | 34 (69) |
| Parity in female recipients, N = 49 | |
| Nulliparous | 14 (29) |
| Parous | 35 (71) |
| Donor/recipient parity, N = 45 | |
| Nulliparous/nulliparous | 5 (11) |
| Nulliparous/parous | 6 (13) |
| Parous/nulliparous | 8 (18) |
| Parous/parous | 26 (58) |
| CMV serostatus, donor/recipient, N = 76 | |
| Negative/negative | 28 (37) |
| Positive/negative | 6 (8) |
| Negative/positive | 8 (11) |
| Positive/positive | 34 (45) |
| Disease type | |
| Hematologic malignancy | 104 (87) |
| Other malignancy | 10 (8) |
| Nonmalignant condition | 5 (4) |
| HLA antigens | |
| A26, N = 117 | 6 (5) |
| DR2, N = 90 | 30 (33) |
| DR3, N = 90 | 23 (26) |
| DR4, N = 90 | 30 (33) |
| DR7, N = 90 | 15 (17) |
| Immunosuppression/graft manipulation, N = 118 | |
| Methotrexate | 16 (14) |
| CD34 selection | 1 (1) |
| CD4 depletion, HIV infection | 1 (1) |
| Conditioning regimen, N = 118 | |
| TBI-containing | 86 (73) |
| BUMELT | 12 (10) |
| Other chemotherapy | 16 (14) |
| None—simple infusion | 4 (3) |
| Cell source | |
| Bone marrow | 88 (74) |
| PBSC | 31 (26) |
| Cell counts | |
| TNC/kg × 108 in BM, N = 80 | 2.1 (0.0-4.8) |
| TMNC/kg × 108 in PBSC, N = 21 | 7.6 (4.7-17.2) |
| CD34/kg × 106 in PBSC, N = 28 | 8.1 (1.5-14.0) |
| Donor buffy coat infusion | 32 (27) |
| Immunotherapy | |
| IL-2 | 9 (8) |
| Anti-idiotype myeloma vaccine | 1 (1) |
| Alpha-interferon | 1 (1) |
| Transplantation year | |
| 1980 to 1987 | 58 (49) |
| 1988 to 1995 | 43 (36) |
| 1996 to 2002 | 18 (15) |
Factor . | No. (%) or mean (range) . |
|---|---|
| Age | 42 (17-68) |
| Sex | |
| Female | 49 (41) |
| Male | 70 (59) |
| Parity in female donors, N = 45 | |
| Nulliparous | 11 (22) |
| Parous | 34 (69) |
| Parity in female recipients, N = 49 | |
| Nulliparous | 14 (29) |
| Parous | 35 (71) |
| Donor/recipient parity, N = 45 | |
| Nulliparous/nulliparous | 5 (11) |
| Nulliparous/parous | 6 (13) |
| Parous/nulliparous | 8 (18) |
| Parous/parous | 26 (58) |
| CMV serostatus, donor/recipient, N = 76 | |
| Negative/negative | 28 (37) |
| Positive/negative | 6 (8) |
| Negative/positive | 8 (11) |
| Positive/positive | 34 (45) |
| Disease type | |
| Hematologic malignancy | 104 (87) |
| Other malignancy | 10 (8) |
| Nonmalignant condition | 5 (4) |
| HLA antigens | |
| A26, N = 117 | 6 (5) |
| DR2, N = 90 | 30 (33) |
| DR3, N = 90 | 23 (26) |
| DR4, N = 90 | 30 (33) |
| DR7, N = 90 | 15 (17) |
| Immunosuppression/graft manipulation, N = 118 | |
| Methotrexate | 16 (14) |
| CD34 selection | 1 (1) |
| CD4 depletion, HIV infection | 1 (1) |
| Conditioning regimen, N = 118 | |
| TBI-containing | 86 (73) |
| BUMELT | 12 (10) |
| Other chemotherapy | 16 (14) |
| None—simple infusion | 4 (3) |
| Cell source | |
| Bone marrow | 88 (74) |
| PBSC | 31 (26) |
| Cell counts | |
| TNC/kg × 108 in BM, N = 80 | 2.1 (0.0-4.8) |
| TMNC/kg × 108 in PBSC, N = 21 | 7.6 (4.7-17.2) |
| CD34/kg × 106 in PBSC, N = 28 | 8.1 (1.5-14.0) |
| Donor buffy coat infusion | 32 (27) |
| Immunotherapy | |
| IL-2 | 9 (8) |
| Anti-idiotype myeloma vaccine | 1 (1) |
| Alpha-interferon | 1 (1) |
| Transplantation year | |
| 1980 to 1987 | 58 (49) |
| 1988 to 1995 | 43 (36) |
| 1996 to 2002 | 18 (15) |
Unless otherwise stated, percentages within a group were calculated using a denominator of 119 patients. TBI indicates total body irradiation; BUMELT, busulfan/melphalan/thiotepa; PBSC, peripheral blood stem cell; TNC, total nuclear cell count; TMNC, total mononuclear cell count, and IL-2, interleukin-2.